FDA — authorised 17 January 1946
- Marketing authorisation holder: B BRAUN
- Status: approved
🇺🇸 Ablysinol in United States
FDA authorised Ablysinol on 17 January 1946
Marketing authorisations
FDA — authorised 22 December 1988
- Application: NDA019357
- Marketing authorisation holder: QOL MEDCL
- Local brand name: ETHAMOLIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 21 June 2018
- Application: NDA207987
- Marketing authorisation holder: BPI LABS
- Local brand name: ABLYSINOL
- Indication: SOLUTION — INTRA-ARTERIAL
- Status: approved
Ablysinol in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Ablysinol approved in United States?
Yes. FDA authorised it on 17 January 1946; FDA authorised it on 22 December 1988; FDA authorised it on 21 June 2018.
Who is the marketing authorisation holder for Ablysinol in United States?
B BRAUN holds the US marketing authorisation.